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The world is currently facing a serious SARS-CoV-2 infection pandemic. This virus is a new isolate of
coronavirus, and the current infection crisis has surpassed the SARS and MERS epidemics that occurred in 2002
and 2013, respectively. SARS-CoV-2 has currently infected more than 142,000 people, causing 5,000 deaths and
spreading across more than 130 countries worldwide. The spreading capacity of the virus clearly demonstrates
the potential threat of respiratory viruses to human health, thereby reiterating to the governments around the
world that preventive health policies and scientific research are pivotal to overcoming the crisis. Coronavirus
disease (COVID-19) causes flu-like symptoms in most cases. However, approximately 15% of the patients need
hospitalization, and 5% require assisted ventilation, depending on the cohorts studied. What is intriguing,
however, is the higher susceptibility of the elderly, especially individuals who are older than 60 years of age, and
have comorbidities, including hypertension, diabetes, and heart disease. In fact, the death rate in this group may
be up to 10-12%. Interestingly, children are somehow less susceptible and are not considered as a risk group.
Therefore, in this review, we discuss some possible molecular and cellular mechanisms by virtue of which the
elderly subjects may be more susceptible to severe COVID-19. Toward this, we raise two main points, i) increased
ACE-2 expression in pulmonary and heart tissues in users of chronic angiotensin 1 receptor (AT1R) blockers; and
ii) antibody-dependent enhancement (ADE) after previous exposure to other circulating coronaviruses. We believe
that these points are pivotal for a better understanding of the pathogenesis of severe COVID-19, and must be
carefully addressed by physicians and scientists in the field.
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’ INTRODUCTION
The world is facing a major public health crisis due to
the pandemic caused by a recently-described coronavirus,
named SARS-CoV-2 (1-3). Reaching proportions that far
surpass those of SARS and MERS, the SARS-CoV-2 epidemic
started in Wuhan, China in December 2019, but has now
spread to more than 130 countries worldwide and has infec-
ted approximately 142,000 people, with more than 5,000
deaths being attributed to it (WHO, March 13th 2020) (4).
Sequencing analysis of the viral genome has revealed muta-
tions in the spike protein—which is essential for SARS-CoV-2
attachment and invasion into host cells—may have favored
the spill over from bats to humans (1). Most patients infected
with coronaviruses develop a mild flu-like disease, in which
the most common symptoms are fever and cough. However,
in a study of 1,099 patients from 552 hospitals from 30
provinces of China in 2020, Guan W et al. (5), revealed that
15.7% of the patients who develop severe disease have
increased difficulty in breathing because of pneumonia.
Radiological imaging of the lungs revealed opacity in 56.4%
of the patients. Approximately 2.7% of the patients needed
assisted ventilation, and 1.4% died (1).
However, coronavirus disease (COVID-19) may rapidly
develop into severe acute respiratory syndrome (SARS) in
elderly subjects (460 yr), especially in those with comorbid-
ities, such as hypertension, diabetes, and pulmonary diseases
(1,4,6). What is intriguing is that, unlike in the case of
influenza (7), children are not included in the risk group,
as very few cases of severe COVID-19 in children have
been reported, and there have been no reports of death
in children under the age of 9. This raises questions
regarding the cellular and molecular mechanisms associated
with the severity of COVID-19. Understanding and elucidat-
ing such mechanisms may greatly improve our know-
ledge of the pathogenesis of the disease, and thus guide
health professionals as to how to better treat the elderly
population.DOI: 10.6061/clinics/2020/e1912
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Toward this, we raise two main points of discussion, i) the
increased angiotensin-converting enzyme-2 (ACE-2) expres-
sion in pulmonary and heart tissues of hypertensive patients
with chronic use of AT1R blockers and ii) antibody-dependent
enhancement (ADE) after previous exposure to other circulat-
ing coronaviruses.
SARS-CoV-2 and ACE-2
After entering the host—usually through aerosolized viral
particles or contact with contaminated surfaces—the virus
needs to undergo its biological cycle. Spike proteins—that
are coded by the S gene in one of the open reading frames
of the viral genome—need to interact with viral receptors
on the surface of host cells. SARS-CoV-2 spike proteins bind
to angiotensin-converting enzyme-2 (ACE-2), which is
expressed in the epithelial cells of the lungs (8,9). This is
the main reason why coronaviruses often cause respiratory
disease. Notably, ACE-2 may also be highly expressed in
intestinal tissues (9), leading to diarrhea, as observed in 60%
of the patients during the SARS-CoV epidemic in 2002. Only
a few patients with SARS-CoV-2 infection had diarrhea,
although viral particles may be detected in the stool (10).
After attaching to the ACE-2 through the receptor-binding
domain (RBD) of the S1 and S2 domains of the spike protein,
the viral envelope fuses with the host cell membrane and is
further internalized. Genetic material, a positive RNA strand
of approximately 20-32 kb, is released into the cytoplasm
for replication (1). Thus, the importance of ACE-2 expression
dynamics for viral infectivity, tropism, and pathogenicity is
evident.
ACE-2, or ACE-related carboxypeptidase, is an 805 amino
acid transmembrane protein which is an important member
of the renin-angiotensin system that plays a pivotal role
in the regulation of blood pressure (11). ACE converts
angiotensin I (Ang I) into angiotensin II (Ang II), whereas
ACE-2 converts Ang II into angiotensin 1-7 (Ang 1-7) or
angiotensin 1-9 (Ang 1-9) (12). Ang II and Ang 1-7 have
antagonizing effects, as Ang II binds to angiotensin 1
receptor (AT1R), inducing vasoconstriction and increase in
blood pressure, whereas Ang 1-7 binds to AT2R, leading to
vasodilatation and decrease in blood pressure (11,12).
As the renin-angiotensin system affects blood pressure and
kidney function, ACE inhibitors and AT1R blockers are
widely used in hypertensive and cardiac patients (13). In this
context, the chronic use of ACE inhibitors or AT1R anta-
gonists may be of particular relevance for patients infected
with SARS-CoV-2, as they may alter the dynamics of ACE-2
expression and thus increase susceptibility to SARS-CoV-2
infection.
It has already been demonstrated by using hypertensive
rat models that AT1R blockade elevates ACE-2 expression.
Treatment with losartan and lisinopril, either alone or in
combination, significantly increases ACE-2 mRNA in cardio-
myocytes of rats. This is associated with higher Ang 1-7
plasma concentrations (14). This was corroborated by analyz-
ing the heart tissue from rats with myocardial infarction that
were treated with losartan (15). Concordantly, olmesartan, a
more effective AT1R antagonist, significantly increased both
cardiac and renal expression of ACE-2 in Wistar–Kyoto rats
(16). This is in agreement with the use of perindopril, an ACE
inhibitor, in rats (17).
Another interesting feature of the dynamics of ACE-2
expression in tissues is its ability to be cleaved from the cell
surface by a metalloproteinase called ADAM17 (TACE) (18).
The ACE-2 ectodomain gets cleaved, releasing soluble ACE-2
(sACE-2), whose role has not been fully elucidated. How-
ever, it has been shown that a higher concentration of sACE-
2 in the plasma correlates with a poorer prognosis after heart
failure (19). Notably, sACE-2 may also be detected at higher
concentrations in the cerebrospinal fluid in hypertensive
patients. This has been corroborated in Nefhcrex AT1aRflox/flox
mice, indicating that ACE-2 and sACE-2 levels in the brain
are associated with the etiology of neurogenic hyperten-
sion (20).
Further, it was demonstrated that ACE-2 may be cleaved
by other mechanisms. For instance, the SARS spike protein
may modulate ADAM17 expression, which in turn cleaves
ACE-2 into its soluble form. This was found to be dependent
on the cytoplasmic domain of ACE-2, as siRNA against
ADAM17 or ACE-2 lacking intracellular domains abrogated
this phenomenon (21). Interestingly, increased shedding of
ACE-2 correlates with worsening of the disease, probably
because of an increase in Ang II instead of Ang 1-7. This
leads to increased vascular permeability and local inflamma-
tion. Interestingly, ACE-2 cleavage from the cell surface may
also occur in lung epithelial cells (22). Thus, cleavage of
ACE-2 into sACE-2 would compromise the effect of Ang 1-7
on AT2R, thereby reducing pulmonary hypertension and
inflammation.
Altogether, as depicted in Figure 1, these data show that
modulating the renin-angiotensin axis alters ACE-2 expres-
sion in several tissues, especially in the lung and heart
tissues. The use of ACE inhibitors and AT1R antagonists
seems to upregulate ACE-2 expression, facilitating viral
attachment and entry. The further presence of the virus itself
or some cytokines, including TNF-a, leads to ACE-2 release
from the cell membrane, abrogating its function to counteract
Ang II.
Altogether, ACE-2 overexpression may facilitate viral
replication in lung tissue and promote lung vascular perme-
ability, a common feature of severe SARS-CoV-2 infection.
In summary, this may greatly impact the outcome of SARS-
CoV-2 infection in elderly and hypertensive patients, as
ACE-2 is the putative attachment and invasion receptor for
coronaviruses (8,23). In fact, the use of TACE inhibitors as
SARS antiviral agents has already been proposed in expe-
rimental models (2,3,24).
’ ANTIBODY-DEPENDENT ENHANCEMENT
ADE is a phenomenon by which viruses use preexisting
non-neutralizing antibodies from previous exposure to
invade host cells through Fc receptor-mediated internaliza-
tion. This is most commonly observed during secondary
dengue virus (DENV) infection, causing severe hemorrhagic
disease (25). Notably, the possibility of ADE between Zika
virus (ZIKV), the causative agent of ZIKV congenital syn-
drome (26), and DENV has been intensely debated recently
(27-29). Moreover, ADE has been the focus of debate for
Ebola (30) and HIV (31) infections.
During ADE, preexisting antibodies elicited during a
previous viral exposure are not able to neutralize viral
particles during a secondary infection with any antigenic-
related virus. Instead, IgG-opsonized viral particles then
target FcgR expressed on endothelial and immune cells,
facilitating viral internalization into host cells. Further,
after intense viral replication, endothelial cells may respond
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by increasing vascular permeability and allowing exu-
date extravasation and bleeding. However, monocytes
become highly activated and may initiate a cytokine
storm (32).
In the context of SARS-CoV-2, it is plausible to think that
ADE occurs. As mentioned in the introduction section,
elderly (460 yr) patients are more susceptible to infection for
unknown reasons. As coronaviruses in general are highly
prevalent in the global population, causing mild infection
and flu-like symptoms, seroconversion into previous circu-
lating coronaviruses is probably widespread. Thus, it is
reasonable to infer that elderly patients, for obvious reasons,
have been exposed to previous infections more times than
younger subjects. This would imply a vaster repertoire of
antibodies against coronavirus epitopes produced by long-
living plasma cells, which in fact has recently been shown to
expand during SARS-CoV-2 infection.
However, whether these antibodies are either neutralizers
or enhancers must be further addressed. It is worth men-
tioning that, concerning the new SARS-CoV-2, sequencing
analysis of the viral genome isolated in Wuhan, China
indicated that mutations mainly occurred within the coding
sequence of the spike protein, which has less than 40%
sequence identity with that of previously circulated corona-
viruses (1). These mutations may be responsible not only for
the spill over from bats to humans, but also for inducing
ADE, as changes in spike epitopes may result in interac-
tions with non-neutralizing antibodies. Corroborating this,
a novel epitope, which was lacking in previous isolates,
was mapped (33).
As COVID-19 is not a hemorrhagic disease, it is probable
that ADE, if present, is not mediated by endothelial cells.
However, it has already been shown that lung epithelial cells
express high levels of FcgRIIa (34). Moreover, immune cells,
including monocytes and dendritic cells, highly express this
receptor. These populations, especially monocytes, greatly
account for the inflammatory infiltrate in the lungs during
pneumonia, which is consistent with the transient lympho-
penia observed in patients as circulating cells may migrate to
the lungs. Conversely, lung imaging of patients with severe
COVID-19 shows a great degree of lung opacity, which
is consistent with edema and cellular infiltrate (5). Thus,
it is feasible that lung-infiltrating monocytes expressing
FcgR greatly favor SARS-CoV-2 replication in the lung tissue,
accounting for the greater susceptibility of the elderly
patients.
Corroborating this hypothesis, young individuals and
children do not represent the risk group for severe disease,
which greatly differs from the case of influenza (7), for
instance. In the context of ADE, it is plausible to think that
children—as they had less or no exposure to previous
circulating coronaviruses—carry a very restricted repertoire
of IgG—or only low-affinity IgM—which is not capable of
inducing ADE. In this context, mapping complementarity
determining regions (CDRs) in IgGs from young and elderly
individuals would be of great importance not only to find
neutralizing antibodies but also to address this hypothesis.
Additionally, previous studies on MERS and SARS have
already highlighted the possibility of ADE. A recent report
published by Wan Y et al. elucidated the mechanism by
Figure 1 - Illustrative scheme of ACE-2 expression in the lungs. Left panel: Normally expressed ACE-2 in the lung tissue interacts with
SARS-CoV-2. Middle panel: Increased expression of ACE-2 in lung tissues of hypertensive patients under chronic treatment with AT1R
blockers. Right panel: ADAM17 cleaves ACE-2, releasing its soluble form, sACE-2, whose levels are increased in the presence of TNF-a.
Illustration was developed by the authors using www.biorender.com.
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which monoclonal antibodies (mAbs) induce ADE in human
cells. Interestingly, mAbs that target the RBD of SARS
and MERS spike proteins induced conformational changes
in the protein that favors an interaction with dipeptidyl
peptidase 4 (DPP4), the receptor for MERS (38). Moreover,
immunocomplexes also promoted viral entry. However,
increasing concentrations of antibodies block viral invasion,
as RBDs become inaccessible.
This is consistent with previous findings by Wang Q et al.
(39) who infected the promonocytic cell line HL-CZ—that
expresses both ACE-2 and FcgR—with SARS-CoV-2 in the
presence of increasing concentrations of anti-sera. Their data
demonstrated that high concentrations of antibodies neu-
tralized the virus, whereas lower concentrations induced
ADE. More interestingly, the anti-sera also recognized spike
protein-related antigens.
Another study on SARS-CoV-2 using Rhesus monkeys
showed that immunization with full-length SPIKE glycopro-
tein led to increased disease severity, mostly to because of an
increase in neutralizing antibodies (NAb) (35). The study
demonstrated that NAbs switched the phenotype of lung-
infiltrating macrophages to a pro-inflammatory M1 profile,
instead of the tissue-healing profile M2. This aggravated
lung injury and greatly contributed to its pathology. Con-
versely, previous studies using samples from deceased
patients suffering from SARS-CoV infection indicated that
NAb titers reached higher levels earlier in these patients,
compared to that in patients who survived (36). This may
indicate that ADE and the role of preexisting antibodies are
in fact very relevant to the overall outcome of the infection.
Thus, as indicated in Figure 2, circulating antibodies,
instead of neutralizing the current circulating SARS-CoV-2,
may bind to viral particles and thus promote Fc-mediated
internalization by lung epithelial cells and infiltrating
monocytes, contributing to the worsening of COVID-19.
These are the most recent and mechanistic studies on ADE of
coronaviruses thus far. Although the data are consistent,
whether the phenomenon of ADE is observed in patients
with severe COVID-19 is yet to be determined. Noteworthy,
however, is the fact that immune complexes of low-avidity
antibodies at sub-optimal concentrations were also respon-
sible for the worsening of the pulmonary disease caused by
H1N1 during the 2009 epidemic (37).
’ CONCLUSIONS
SARS-CoV-2 is the newest threat to human health and
needs emergency action from governments and public health
agencies worldwide, especially because of its pandemic
potential as recently declared by the World Health Organiza-
tion (WHO). In this context, it is essential to rapidly and
deeply address all the possibilities concerning the severity of
infection, especially in the elderly population that accounts
for approximately 10-12% of the mortality rate. Here, we
present several relevant aspects that may contribute to the
increased susceptibility of the aforementioned population to
COVID-19. We believe that i) increased expression of ACE-2
in hypertensive patients being treated with ACE inhibitors
and AT1R blockers and ii) previous exposure to circulating
coronaviruses with low neutralizing capacity to SARS-CoV-2
Figure 2 - Illustrative scheme of ADE during SARS-CoV-2 infection. Left panel: First infection and lack of preexisting antibodies allow
viral particles to interact with ACE-2. Middle panel: Preexisting low-affinity antibodies or antibodies at sub-optimal concentrations
bind to viral particles and facilitate the viral internalization mediated by FcRs expressed on either the epithelial or immune cells. Right
panel: Neutralizing IgGs elicited in response to vaccination, or neutralizing IgM that do not mediate enhancement bind to viral
particles. Illustration created by the authors using www.biorender.com.
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may greatly contribute to the increased susceptibility of the
elderly patients to COVID-19. To determine whether these
hypotheses are correct, further investigations are needed,
not only to better understand the etiology of the current
SARS-CoV-2 infection, but also to be better prepared for
future epidemics.
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